Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Fokus auf Impfstoffe gegen Infektionskrankheiten mit hohem ungedecktem Bedarf Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • Forschung & Entwicklung
    Forschung & Entwicklung Innovation in der Forschung und Entwicklung von Impfstoffen. Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Finanzen & Einreichungen
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance und Ethik
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Pressemeldungen

April 7, 2010

VIVALIS ACHIEVES SIGNIFICANT MILESTONE WITH GLAXOSMITHKLINE BIOLOGICALS IN THE DEVELOPMENT OF HUMAN FLU VACCINES BASED ON THE EB66® CELL LINE

April 6, 2010

2009: commercial and technological successes, solid financial position confirmed

April 2, 2010

PARTICIPATION IN SMALLCAP EVENT 12 & 13 APRIL 2010 IN PARIS

February 16, 2010

VIVALIS SIGNE UNE NOUVELLE LICENCE DE RECHERCHE AVEC KYOTO BIKEN POUR L’EVALUATION DE LA LIGNEE CELLULAIRE EB66® POUR LA PRODUCTION DE VACCINS VIRAUX

January 27, 2010

2009 TARGETS MET

January 18, 2010

2010 FINANCIAL CALENDAR

January 11, 2010

VIVALIS ANNOUNCES THE STRATEGIC ACQUISITION OF HUMALYS AND THE ADDITION OF A NEW PLATFORM FOR GENERATING HUMAN MONOCLONAL ANTIBODIES Nantes

December 22, 2009

VIVALIS SIGNS A NEW COMMERCIAL LICENSE IN THE VETERINARY VACCINE FIELD

December 1, 2009

VIVALIS enters NYSE Euronext indexes SBF 250 and CAC Small 90

October 27, 2009

VIVALIS EXPANDS AGREEMENT WITH SANOFI-AVENTIS IN THE THERAPEUTIC PROTEINS FIELD

  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 47

Valneva

  • Über uns
  • Produkte
  • Forschung & Entwicklung
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2022 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT